利妥昔单抗治疗伴蛋白尿和肾功能损害的IgA肾病:一项随机对照试验
这项开放标签、多中心随机对照试验纳入34例经活检证实、蛋白尿>1 g/d且eGFR<90 ml/min/1.73 m²的成人IgA肾病患者,随机接受标准治疗或利妥昔单抗联合标准治疗,随访1年。结果显示利妥昔单抗虽有效清除B细胞且耐受良好,但未显著改善肾功能或蛋白尿,也未降低血清半乳糖缺陷型IgA1及其抗体水平。
要点
- 利妥昔单抗有效清除B细胞且耐受良好。
- 两组eGFR均无变化,利妥昔单抗未改变蛋白尿水平。
- 每组各有3例患者蛋白尿较基线降低≥50%。
核心结论
- 在本试验中,利妥昔单抗治疗1年未显著改善肾功能或蛋白尿。
- 利妥昔单抗虽有效清除B细胞,但未能降低血清半乳糖缺陷型IgA1及抗半乳糖缺陷型IgA1抗体水平。
- 利妥昔单抗缺乏疗效可能反映其未能降低在IgA肾病中起关键致病作用的特异性抗体水平,至少在该阶段和严重程度的IgA肾病中如此。
研究设计与样本
- 开放标签、多中心随机对照试验,随访1年。
- 纳入34例经活检证实的成人IgA肾病患者,蛋白尿>1 g/d,维持使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂且血压控制良好,eGFR<90 ml/min/1.73 m²。
- 随机分为标准治疗组或利妥昔单抗联合标准治疗组。
- 主要结局指标包括蛋白尿变化和eGFR变化。
- 基线血清肌酐中位数(范围)为1.4(0.8-2.4)mg/dl,蛋白尿为2.1(0.6-5.3)g/d。
主要发现
- 利妥昔单抗治疗清除了B细胞且耐受良好。
- 两组eGFR均无变化。
- 利妥昔单抗未改变蛋白尿水平,与基线或对照组相比均无差异;每组各有3例患者蛋白尿水平降低≥50%。
- 血清半乳糖缺陷型IgA1或抗半乳糖缺陷型IgA1抗体水平均无变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgA nephropathy frequently leads to progressive CKD. Although interest surrounds use of immunosuppressive agents added to standard therapy, several recent studies have questioned efficacy of these agents. Depleting antibody-producing B cells potentially offers a new therapy. In this open label, multicenter study conducted over 1-year follow-up, we randomized 34 adult patients with biopsy-proven IgA nephropathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP and eGFR<90 ml/min per 1.73 m2, to receive standard therapy or rituximab with standard therapy. Primary outcome measures included change in proteinuria and change in eGFR. Median baseline serum creatinine level (range) was 1.4 (0.8-2.4) mg/dl, and proteinuria was 2.1 (0.6-5.3) g/d. Treatment with rituximab depleted B cells and was well tolerated. eGFR did not change in either group. Rituximab did not alter the level of proteinuria compared with that at baseline or in the control group; three patients in each group had ≥50% reduction in level of proteinuria. Serum levels of galactose-deficient IgA1 or antibodies against galactose-deficient IgA1 did not change. In this trial, rituximab therapy did not significantly improve renal function or proteinuria assessed over 1 year. Although rituximab effectively depleted B cells, it failed to reduce serum levels of galactose-deficient IgA1 and antigalactose-deficient IgA1 antibodies. Lack of efficacy of rituximab, at least at this stage and severity of IgA nephropathy, may reflect a failure of rituximab to reduce levels of specific antibodies assigned salient pathogenetic roles in IgA nephropathy.
引用
- Lafayette RA, Canetta PA, Rovin BH, et al. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. J Am Soc Nephrol. 2016. PMID: 27821627. doi:10.1681/ASN.2016060640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。